Mark Cuban

June 8, 2023

Study finds Mark Cuban’s Cost Plus Drug Company could save taxpayers millions on Medicare generic oncology drugs

Vanderbilt research finds that the U.S. government could save taxpayers between $228 million-$2.15 billion a year if insurers who operate its Medicare Part D plans purchased seven generic oncology drugs at the same prices obtained by the Mark Cuban Cost Plus Drug Company.

By Craig Boerner

March 24, 2023

Miss the discussion with Mark Cuban? Watch the recording here.

By VUMC News and Communications

February 9, 2023

Mark Cuban pharmacy could save billions on prostate cancer, bladder drugs

Vanderbilt research found that a new drug company founded by entrepreneur Mark Cuban could save patients $1.29 billion a year based on 2020 Medicare Part D expenditures on just the nine most popular urological drugs.

By Craig Boerner